Sat Kartar Shopping IPO
Sat Kartar Shopping Ltd
₹1,23,200 /1600 sharesMinimum Investment
Sat Kartar Shopping IPO Listing Details
Listed On | Issue Price | Listing Price | Listing Gains |
---|
-- | ₹81.00 | ₹153.90 | ₹72.90 (90.00%) |
Sat Kartar Shopping IPO Details
Bidding Dates | Min. Investment | Lot Size | Price Range |
---|
10 Jan ‘25 - 14 Jan ‘25 | ₹1,23,200 | 1,600 | ₹77 - ₹81 |
Qualified Institutional Buyers | 91.44x |
Non-Institutional Investor | 362.22x |
Retail Individual Investor | 179.31x |
Total | 178.34x |
Sat Kartar Shopping is an Ayurveda-focused healthcare company offering natural wellness solutions across various therapeutic areas and lifestyle needs. Initially combining Ayurveda and spiritual product lines, the company has since streamlined its operations to concentrate solely on Ayurveda. Operating in the direct-to-consumer (D2C) segment, Sat Kartar Shopping sells its products through its own website, third-party e-commerce platforms, TV marketing, and digital channels like Google and Meta. Its key products include Addiction Killer, Liv Muztang, Kaama Gold, Ayush 82 Aadved for diabetes and blood sugar management, and joint pain relief solutions.;
Managing director
Mr. Ved Prakash
Parent organisation
Sat Kartar Shopping Ltd
Strengths & Financials of Sat Kartar Shopping
Sat Kartar Shopping offers a portfolio of over 50 SKUs, categorised into niche therapeutic areas addressing specific health issues and lifestyle-based solutions.
The company claims to provide nationwide availability of its products. The company also delivers to metropolitan areas as well as Tier 1, Tier 2, and Tier 3 cities through delivery partners.
Sat Kartar Shopping has an in-house research and development (R&D) team comprising Bachelor of Ayurvedic Medicine and Surgery (BAMS) doctors who create specialised formulations, which are then produced by contract manufacturers.
The company claims to have successfully conducted clinical trials for products like Liv Muztang, Dr. Piles Free, and Dr. Madhu Amrit. These trials have demonstrated product efficacy and have been documented in the World Journal of Pharmaceutical Research, it further claims.
The company has seen a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 51.92 crore in FY22 to Rs 82.97 crore in FY23 to Rs 127.91 crore in FY24. PAT increased from Rs 1.39 crore in FY22 to Rs 2.51 crore in FY23 to Rs 6.30 crore in FY24.
A major portion of the company's revenue comes from five states—Tamil Nadu, Uttar Pradesh, Karnataka, Maharashtra, and Andhra Pradesh. These states contributed Rs 60.66 crore (55.50%) as of December 15, 2024, and Rs 66.82 crore (52.24%), Rs 40.53 crore (48.84%), and Rs 31.94 crore (61.52%) in FY24, FY23, and FY22, respectively, to the revenue from operations. Any adverse developments in these regions could negatively affect the company's revenue and overall performance.
The formulations for the company's products are registered under the names of the manufacturers rather than the company itself.
The company operates in a highly competitive segment, where entry barriers are low.
The company relies on its individual promoters and management team to manage its operations. Losing key personnel or failing to attract, retain, and motivate qualified staff could negatively impact its operations and financial performance.
The company's promoters are currently involved in certain ongoing legal proceedings. Any adverse judgments in any of these cases could be detrimental to the company’s business prospects.
As of December 15, 2024, the company has outstanding secured borrowings amounting to Rs 1.01 crore and unsecured borrowings totalling Rs 3.01 crore. Any inability to repay or service these loans could adversely affect the company’s financial position.
The company does not own any manufacturing facilities. All its products are manufactured by third parties. This leaves the company at risk of unexpected interruption of supplies and the quality of products not being as per the company’s quality requirements. This can result in losses for the company.
Sat Kartar Shopping Financials
*All values are in Rs. Cr
Application Details of Sat Kartar Shopping IPO
Apply as | Price band | Apply upto |
---|
Regular | ₹77 - 81 | ₹2 - 5 Lakh |
High Networth Individual | ₹77 - 81 | ₹2 - 5 Lakh |
For Sat Kartar Shopping IPO, eligible investors can apply as Regular.